OncoOne Entered into an Agreement with GenScript ProBio for the Manufacturing of Monoclonal Antibody Therapies Targeting oxMIF
Shots:
- The companies collaborated to develop cell line, drug substance, and drug product manufacturing of therapeutic and diagnostic mAbs directed against the immuno-oncology target oxMIF for the treatment of multiple solid tumors. oxMIF combines with CDx for precise detection and targeted treatment
- Both companies will combine their expertise in drug discovery and manufacturing to develop the mAb product into the clinic
- OncoOne is expected to initiate P-I clinical trials for its ON203 as a therapeutic program & ON102 as a companion radio-labeled diagnostic in 2023
Ref: PRNewswire | Image: GenScript ProBio
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com